Want to see IN:HCG full AI Analyst Report?
Top Page
HealthCare Global Enterprises Ltd.
(HCG)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹778.00
▲(16.77% Upside)
Action:Reiterated
Date:08/21/26
The score is primarily held back by weak profitability and a leveraged balance sheet despite strong operating cash flow trends. Technical indicators are constructive and support near-term momentum, but the very high P/E meaningfully reduces the overall attractiveness.
Positive Factors
Revenue Scale and Expansion
The substantial five-year revenue increase indicates expanding patient activity and a larger operating base. HCG’s integrated oncology network spans screening, diagnostics, treatment and follow-up care, supporting durable demand across the cancer-care continuum.
Negative Factors
High and Rising Leverage
Debt materially exceeds equity and has increased substantially over recent years. This debt-heavy structure can raise interest and refinancing exposure, constrain capital allocation and make earnings more sensitive to changes in hospital utilization or operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale and Expansion
The substantial five-year revenue increase indicates expanding patient activity and a larger operating base. HCG’s integrated oncology network spans screening, diagnostics, treatment and follow-up care, supporting durable demand across the cancer-care continuum.
Read all positive factors
HealthCare Global Enterprises Ltd. (HCG) vs. iShares MSCI India ETF (INDA)
Market Cap
₹102.71B
Dividend YieldN/A
Average Volume (3M)48.48K
Price to Earnings (P/E)442.7
Beta (1Y)0.48
Revenue Growth13.65%
EPS Growth-40.97%
CountryIN
Employees6,761
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.56
Shares Outstanding149,302,200
10 Day Avg. Volume77,365
30 Day Avg. Volume48,484
Financial Highlights & Ratios
PEG Ratio-7.78
Price to Book (P/B)5.59
Price to Sales (P/S)2.93
P/FCF Ratio135.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9
Revenue Forecast (FY)₹29.06B
HealthCare Global Enterprises Ltd. Business Overview & Revenue Model
Company Description
HealthCare Global Enterprises Limited, founded in 1989 and headquartered in Bengaluru, India, delivers comprehensive healthcare services with a primary focus on oncology. The company offers a full spectrum of cancer care, from diagnosis to various...
How the Company Makes Money
HCG primarily generates revenue by delivering cancer-care services to patients through its hospital network. Key revenue streams typically include (i) inpatient and outpatient oncology treatment services (such as surgical oncology, medical oncolog...
HealthCare Global Enterprises Ltd. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
54
Neutral
Cash Flow
71
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.20B | 25.38B | 22.23B | 19.12B | 16.94B | 13.98B |
| Gross Profit | 10.25B | 12.97B | 11.91B | 10.48B | 9.20B | 7.52B |
| EBITDA | 4.68B | 4.48B | 3.13B | 2.67B | 2.37B | 1.78B |
| Net Income | 227.80M | 137.60M | 444.10M | 481.55M | 293.49M | 537.33M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 39.23B | 35.43B | 27.07B | 23.16B | 22.20B |
| Cash, Cash Equivalents and Short-Term Investments | 5.41B | 5.52B | 3.53B | 3.03B | 1.97B | 2.04B |
| Total Debt | 0.00 | 17.35B | 18.37B | 12.74B | 9.01B | 9.15B |
| Total Liabilities | -14.10B | 25.12B | 25.53B | 18.42B | 14.47B | 13.36B |
| Stockholders Equity | 14.10B | 13.32B | 9.22B | 8.26B | 8.61B | 8.70B |
Cash Flow | ||||||
| Free Cash Flow | 339.30M | 550.00M | 1.08B | 988.99M | 1.18B | 1.49B |
| Operating Cash Flow | 1.92B | 3.47B | 3.17B | 2.85B | 2.52B | 2.20B |
| Investing Cash Flow | -580.00M | -1.77B | -4.88B | -2.26B | -1.33B | 1.25B |
| Financing Cash Flow | -806.50M | 2.41B | -424.40M | -640.16M | -1.40B | -1.55B |
HealthCare Global Enterprises Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹382.32B | 69.01 | ― | 0.07% | 21.27% | 4.09% | |
64 Neutral | ₹693.20B | 128.10 | ― | 0.51% | 15.70% | -2.76% | |
63 Neutral | ₹102.71B | 442.69 | ― | ― | 13.65% | -40.97% | |
60 Neutral | ₹685.50B | 65.42 | ― | 0.11% | 17.50% | 20.65% | |
59 Neutral | ₹1.26T | 60.81 | ― | 0.23% | 17.20% | 32.79% | |
55 Neutral | ₹964.23B | 66.33 | ― | 0.20% | 15.96% | 26.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:HCG
HealthCare Global Enterprises Ltd.
711.95
20.43
2.95%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,960.00
1,052.23
13.31%
IN:ASTERDM
Aster DM Healthcare Ltd.
780.05
138.45
21.58%
IN:FORTIS
Fortis Healthcare Ltd.
911.90
-54.33
-5.62%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,036.50
-142.15
-12.06%
IN:MEDANTA
Global Health Limited
1,479.75
112.88
8.26%
HealthCare Global Enterprises Ltd. Corporate Events
HealthCare Global Publishes Q1 FY27 Unaudited Results in Line with SEBI Norms
Aug 8, 2026
HealthCare Global Enterprises Ltd. has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as approved by its board on August 6, 2026. The results have been advertised in leading English and K...
HealthCare Global opens special window for legacy physical share demat
Jul 25, 2026
HealthCare Global Enterprises Ltd. announced that, in line with a recent SEBI circular, a special window will be open from February 5, 2026, to February 4, 2027, to allow transfer and dematerialisation of physical securities that were bought or so...
HealthCare Global Closes Trading Window Ahead of Q1 FY27 Results
Jun 30, 2026
HealthCare Global Enterprises Ltd. announced that its trading window for dealing in company securities will be closed from July 1, 2026, until 48 hours after the announcement of its standalone and consolidated financial results for the quarter end...
HCG Unit Ethics Committee Hit With 24-Month Clinical Trial Suspension
Jun 17, 2026
HealthCare Global Enterprises disclosed that India’s Central Drugs Standard Control Organization has ordered a 24‑month suspension of the HCG Bangalore Institute of Oncology KR Unit Ethics Committee from approving or overseeing any new...
HCG Seeks Shareholder Nod for ESOP Scheme, Director Reappointment and CEO Pay Revision via Postal Ballot
Jun 8, 2026
HealthCare Global Enterprises Ltd. has initiated a postal ballot process to seek shareholder approval via remote e-voting on a series of special resolutions, including the launch of the HCG Employee Stock Option Scheme 2026 and related grants to g...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.